Previous 10 | Next 10 |
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Good morning, investor! In preparation for another busy day of trading, we’ve put together a list of the biggest pre-market stock movers for Thursday! Source: ventdusud / Shutterstock.com We’ve got ear...
Gainers: BioCardia BCDA +32%. Biophytis BPTS +17%. Mersana Therapeutics MRSN +7%. Liquidia (NASDAQ:LQDA) +5%. Vaccitech (NASDAQ:VACC) +3%. Losers: Kiromic BioPharma KRBP -17%. Mainz Biomed (NASDAQ:MYNZ) -9%. Vaccinex (NASDAQ:VCNX) -7%. NeuroBo Phar...
Kiromic BioPharma's (KRBP) former chair of the audit committee, Pietro Bersani was appointed as interim CEO to succeed Dr. Maurizio Chiriva who departed from his role of CEO and Chairman of Board of Directors as of January 27, 2022. “I have been a member of the Kiromic Board ...
Pietro Bersani, Formerly Board Audit Chair, is Appointed as New Interim Chief Executive Officer Company Director Michael Nagel Appointed as New Chairman of the Board Company Disclosure Committee Created Kiromic BioPharma, Inc. (NASDAQ: KRBP) (“Kiromi...
– Frank Tirelli Will Serve as Chair of Kiromic’s Audit Committee – – Dr. Reeves Brings Deep Biopharmaceutical, Regulatory, and Clinical Expertise to Board Role – Kiromic BioPharma, Inc. (NASDAQ: KRBP) (“Kiromic” or t...
NEW YORK, Dec. 22, 2021 (GLOBE NEWSWIRE) -- Diamond Equity Research, a leading equity research firm with a focus on small capitalization public companies has initiated coverage of Kiromic BioPharma, Inc. (NASDAQ:KRBP). The in-depth 24-page initiation report includes detailed information on ...
Gainers: Galera Therapeutics (NASDAQ:GRTX) +116%, Alzamend Neuro (NASDAQ:ALZN) +18%, Soliton (NASDAQ:SOLY) +12%, Kiromic BioPharma (NASDAQ:KRBP) +6%, Biofrontera (NASDAQ:BFRI) +5%. Losers: Adagio Therapeutics (NASDAQ:ADGI) -78%, Adagio Th...
Kiromic BioPharma, Inc. (NASDAQ: KRBP) (“Kiromic” or the “Company”) , a clinical-stage fully integrated biotherapeutics company using its proprietary DIAMOND ® artificial intelligence (AI) and big data mining platform to discover and develop ...
Gainers: Inspira Technologies (NASDAQ:IINN) +54%, SeqLL (NASDAQ:SQL) +46%, Ocugen (NASDAQ:OCGN) +27%, Aziyo Biologics (NASDAQ:AZYO) +15%, Roivant Sciences (NASDAQ:ROIV) +14%. Losers: Evaxion Biotech (NASDAQ:EVAX) -14%, Kiromic BioPharma (...
Gainers: IceCure Medical (NASDAQ:ICCM) +15%, Kiromic BioPharma KRBP +12%, Eargo (NASDAQ:EAR) +12%, Context Therapeutics (NASDAQ:CNTX) +11%, Xeris Biopharma XERS +11%. Losers: ERYTECH Pharma ERYP -39%, Eyenovia EYEN -37%, Es...
News, Short Squeeze, Breakout and More Instantly...
Kiromic BioPharma Inc. Company Name:
KRBP Stock Symbol:
NASDAQ Market:
Kiromic BioPharma Inc. Website:
Enrollment in the Expansion Phase Expected to Commence in September Deltacel Safety Confirmed at Day 30 in Trial’s Fifth Patient; Efficacy Results on this Patient Expected in August Kiromic BioPharma, Inc. (OTCQB: KRBP) (“Kiromic” or the “Company...
Follow-up Findings Show Stable Disease FDA and IRB Approve IND for a Single-Use, Single-Patient Treatment with Deltacel Fast Track Designation Request Submitted to FDA Complete Enrollment in Trial’s Second Cohort Expected in July Kiromic BioPharma, Inc. ...
Favorable Follow-up Findings Include Stable Disease and a 13% Decrease in Tumor Size Kiromic BioPharma, Inc. (OTCQB: KRBP) (“Kiromic” or the “Company”) reports favorable six-month follow-up results from the first patient enrolled in the Deltacel-01 Phase ...